There are studied the carbohydrate metabolism changes in patients with arterial hypertension under influence of pharmacogenetically determined treatment dependently on genes polymorphisms of angiotensin-converting enzyme (ACE, I/D), in the, first type receptor of angiotensin II (AGTR1, А1166С), β1-adrenergic receptor (ADRβ1, Arg389Gly), peroxisome proliferators-activated receptor-γ2 (PPAR-γ2, Pro12Ala), endothelial NO-synthase (eNOS, t894g). Pharmacogenetically determined treatment during 9–12 months increases the number of patients with plasma glucose level and НОМА-IR index below “threshold” by 8.0 and 13.9% accordingly (р<0,001).
